SCHEMBL4138452

SCHEMBL4138452

CC(C)(C)OC(=O)N1Cc2[nH]ncc2C(O)C1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.47
PSEN1 P49768 1/20 0.47
PSEN2 P49810 1/20 0.47
APH1B Q8WW43 1/20 0.47
NCSTN Q92542 1/20 0.47
APH1A Q96BI3 1/20 0.47
PSENEN Q9NZ42 1/20 0.47
NAMPT P43490 2/20 0.45
KDM4E B2RXH2 2/20 0.39
IDO1 P14902 1/20 0.38
TDO2 P48775 1/20 0.38
ACACB O00763 5/20 0.36
PREP P48147 1/20 0.36
PIK3CD O00329 1/20 0.36
MAPT P10636 1/20 0.36
THRB P10828 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6890800 0.77 NR1H2 (0.62) NR1H2PSEN1PSEN2APH1BNCSTN
SCHEMBL5185542 0.74 NR1H2 (0.37) NR1H2NAMPTTHRB
SCHEMBL28036860 0.74 PSEN1 (0.42) NR1H2PSEN1PSEN2APH1BNCSTN
SCHEMBL28823116 0.74 PSEN1 (0.42) NR1H2PSEN1PSEN2APH1BNCSTN
SCHEMBL20557473 0.74 NR1H2 (0.49) NR1H2PSEN1PSEN2APH1BNCSTN
SCHEMBL8223979 0.74 NR1H2 (0.55) NR1H2PSEN1PSEN2APH1BNCSTN
SCHEMBL28037315 0.73 PSEN1 (0.42) NR1H2PSEN1PSEN2APH1BNCSTN
SCHEMBL28037309 0.73 PSEN1 (0.42) NR1H2PSEN1PSEN2APH1BNCSTN
SCHEMBL24326349 0.73 NAMPT (0.47) NR1H2NAMPTMAPK1
SCHEMBL24209455 0.73 NR1H2 (0.45) NR1H2PSEN1PSEN2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090018329-A1 NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTIBACTERIALS AND BETA-LACTAMASE INHIBITORS NOVEXEL (FR) 2009-01-15 US disclosed
US-7439253-B2 Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors NOVEXEL (FR) 2008-10-21 US disclosed
US-7288549-B2 Heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents AVENTIS PHARMA S.A. (FR) 2007-10-30 US disclosed
US-20050245505-A1 Novel heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents ENTASIS THERAPEUTICS LIMITED (GB) 2005-11-03 US disclosed
US-20040157826-A1 Novel heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors AVENTIS PHARMA S.A. (FR) 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157826-A1 Novel heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors GAA, ALPI, GANAB NR1H2 2807/4885PSEN1 1203/4885PSEN2 2223/4885
US-20050245505-A1 Novel heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents FDPS, MRPL21, DHPS NR1H2 2718/4885PSEN1 3601/4885PSEN2 3830/4885
US-20090018329-A1 NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTIBACTERIALS AND BETA-LACTAMASE INHIBITORS GAA, GANAB, ALPI NR1H2 2663/4885PSEN1 1362/4885PSEN2 2166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.